Public-registry site landscape for NCT02399137, a Pancreatic Cancer study sponsored by Merrimack Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02399137 (registry record) |
| Sponsor | Merrimack Pharmaceuticals |
| Condition(s) | Pancreatic Cancer |
| Phase | PHASE2 |
| Listed sites | 66 |
| Site countries | United States, Canada, Germany, Poland, Spain, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT02399137 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →